CORDIS
EU research results

CORDIS

English EN
Exploitation of Glycosylation Signatures for Precision Medicine

Exploitation of Glycosylation Signatures for Precision Medicine

Objective

GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive changes occur in the glycomics profiles or - Glycan Signatures - of human glycoproteins during progression of many chronic diseases including cancer and inflammatory conditions. The three beneficiaries of the GlySign Consortium have been instrumental in contributing to knowledge in this field through development of glycomics technology and discovery of clinically important novel glycan biomarkers in a variety of diseases.
Glycan signatures have great potential for adding useful diagnostic and prognostic information in PM. However, advancement of this field is slow because (a) glycans have immense structural complexity resulting in major technical challenges for their analysis and (b) there is a lack of experts with required glycoanalytical skills. GlySign will address this gap by training six young scientists within an innovative training-by-research programme with high industrial-academic mobility to eventually push forward the translation of novel glycomics-based diagnostic tools into clinical practice. This will be achieved by further developing a range of selective and sensitive glycomics technologies for the analysis of samples from patients and healthy controls in close collaboration between industry/academia as well as clinical chemists and clinicians who will be the end users of GlySign’s final products. To this end, we will focus the training on clinical glycomics applied to four model diseases implicating changes in the glycosylation of circulating proteins specific to disease progression or subtype, i.e. diabetes, prostate cancer, fetal and neonatal alloimmune thrombocytopenia and rheumatoid arthritis. Due to its strong industrial and translational focus, GlySign will, moreover, fill a current gap in the market by establishing new in vitro diagnostic platforms for clinical exploitation of glycomic biomarkers for PM.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 510 748,56

Participants (2)

Sort alphabetically

Sort by EU Contribution

Expand all

LUDGER LIMITED

United Kingdom

EU Contribution

€ 546 575,76

GENOS DOO ZA VJESTACENJE I ANALIZU

Croatia

EU Contribution

€ 495 522

Partners (4)

Sort alphabetically

Expand all

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

PROZOMIX LIMITED

Stichting Sanquin Bloedvoorziening

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Project information

Grant agreement ID: 722095

Status

Ongoing project

  • Start date

    1 October 2016

  • End date

    30 September 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 1 552 846,32

  • EU contribution

    € 1 552 846,32

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands